STOCK TITAN

AnaptysBio (ANAB) investors back director slate, auditor and equity plan changes

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

AnaptysBio, Inc. held its 2026 Annual Meeting of Stockholders on August 11, 2026 and reported the results of four proposals. Two Class III directors, Hollings Renton and John P. Schmid, were elected to three-year terms expiring at the 2029 annual meeting. Renton received 15,304,522 shares for and 6,613,642 withheld/abstaining votes, while Schmid received 20,314,669 shares for and 1,603,495 withheld/abstaining votes; each proposal had 2,084,465 broker non-votes. Stockholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2027, with 22,343,352 shares for and 1,640,401 against. They also gave non-binding advisory approval to named executive officer compensation with 21,274,791 shares for and approved an amendment to the 2017 Equity Incentive Plan with 15,563,882 shares for.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Votes for Hollings Renton 15,304,522 shares Election of Class III director at 2026 Annual Meeting
Votes for John P. Schmid 20,314,669 shares Election of Class III director at 2026 Annual Meeting
Votes for KPMG LLP ratification 22,343,352 shares Ratification of independent registered public accounting firm for fiscal year ending June 30, 2027
Votes for say-on-pay 21,274,791 shares Non-binding, advisory approval of compensation paid to named executive officers
Votes for equity plan amendment 15,563,882 shares Approval of amendment to the 2017 Equity Incentive Plan
broker non-votes financial
"Broker Non-Votes 2,084,465"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding, advisory approval financial
"Non-binding, advisory approval of compensation paid to the Company’s named executive officers"
independent registered public accounting firm financial
"Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Equity Incentive Plan financial
"Approval of the amendment to the Company’s 2017 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

What did AnaptysBio (ANAB) stockholders decide at the 2026 annual meeting?

Stockholders elected two Class III directors, ratified KPMG LLP as auditor for fiscal 2027, approved on a non-binding basis executive compensation, and approved an amendment to the 2017 Equity Incentive Plan, all based on reported vote tallies.

How did AnaptysBio (ANAB) vote on its Class III director nominees in 2026?

Hollings Renton received 15,304,522 shares for and 6,613,642 withheld/abstaining, while John P. Schmid received 20,314,669 shares for and 1,603,495 withheld/abstaining. Each director vote included 2,084,465 broker non-votes reported.

Was KPMG LLP ratified as AnaptysBio (ANAB) auditor for fiscal 2027?

Yes. Stockholders ratified KPMG LLP as AnaptysBio’s independent registered public accounting firm for the fiscal year ending June 30, 2027, with 22,343,352 shares for, 1,640,401 against, and 18,876 withheld/abstaining, according to the reported voting results.

How did AnaptysBio (ANAB) stockholders vote on executive compensation in 2026?

Stockholders gave non-binding, advisory approval to compensation paid to named executive officers, with 21,274,791 shares for, 609,979 against, 33,394 withheld/abstaining, and 2,084,465 broker non-votes. This reflects support for the disclosed executive pay program on an advisory basis.

What happened with AnaptysBio’s (ANAB) 2017 Equity Incentive Plan at the 2026 meeting?

Stockholders approved an amendment to the 2017 Equity Incentive Plan, with 15,563,882 shares for, 6,332,813 against, 21,469 withheld/abstaining, and 2,084,465 broker non-votes. The amendment’s detailed terms are contained in the referenced plan amendment exhibit.

Which proposals at AnaptysBio’s (ANAB) 2026 meeting had broker non-votes?

Broker non-votes of 2,084,465 shares were reported for four proposals: election of Hollings Renton, election of John P. Schmid, the advisory vote on executive compensation, and approval of the amendment to the 2017 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false000137005300013700532026-08-112026-08-11

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

 

 

ANAPTYSBIO, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-37985

20-3828755

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10770 Wateridge Circle, Suite 210

 

San Diego, California

 

92121

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 858 362-6295

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common stock, par value $0.001 per share

 

ANAB

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 11, 2026, AnaptysBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders and the following proposals were adopted:

 

1.
Election of two Class III directors, Hollings Renton and John P. Schmid, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders or until such time as his respective successor has been duly elected and qualified or until such director’s earlier resignation or removal:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nominees

 

Shares For

 

Shares Withheld / Abstaining

 

Broker Non-Votes

Hollings Renton

 

15,304,522

 

6,613,642

 

2,084,465

John P. Schmid

 

20,314,669

 

1,603,495

 

2,084,465

 

2.
Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares For

 

Shares Against

 

Shares Withheld/Abstaining

 

Broker Non-Votes

22,343,352

 

1,640,401

 

18,876

 

-

 

3.
Non-binding, advisory approval of compensation paid to the Company’s named executive officers:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares For

 

Shares Against

 

Shares Withheld/Abstaining

 

Broker Non-Votes

21,274,791

 

609,979

 

33,394

 

2,084,465

 

4.
Approval of the amendment to the Company’s 2017 Equity Incentive Plan:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares For

 

Shares Against

 

Shares Withheld/Abstaining

 

Broker Non-Votes

15,563,882

 

6,332,813

 

21,469

 

2,084,465

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

 

 

10.1

Amendment No. 1 to AnaptysBio, Inc. Amended and Restated 2017 Equity Incentive Plan.

104

Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ANAPTYSBIO, INC.

 

 

 

 

Date:

August 11, 2026

By:

/s/ Christopher M. Murphy

 

 

 

Christopher M. Murphy
Chief Financial Officer

 


Filing Exhibits & Attachments

2 documents